Data have also been accruing on the neuroprotective properties of PPARγ agonists in models of CNS injury, ischemic stroke, and diseases of the CNS including multiple sclerosis, ALS, and Parkinson's disease [77–80]. This evidence concerns the gene PPARG and multiple sclerosis.